论文部分内容阅读
急性心肌梗塞尤其Q波梗塞,80%～90%病例由冠脉腔内血栓形成致完全闭塞,造成心肌急性缺血性坏死而引起。如能在梗塞后4～6小时内进行溶栓治疗,恢复心肌的再灌注,对缩小急性心梗范围、减少并发症、降低病死率有极其重要的作用。一、常用溶栓剂及其临床应用(一) 第一代溶栓剂:尿激酶和链激酶为第一代溶栓剂,属非特异性溶栓剂。其溶栓机理是由于尿、链激酶可同时激活血浆和血栓内的纤溶酶原,使之转变为有活性的纤溶酶,导致血浆中多种蛋白质降解,血浆中纤维蛋白及纤维蛋白酶原的降解物
In particular, acute myocardial infarction Q wave infarction, 80% to 90% of cases caused by coronary thrombosis completely occluded, causing acute myocardial ischemia and necrosis caused. If the infarction in 4 to 6 hours after thrombolytic therapy to restore myocardial reperfusion, to narrow the scope of acute myocardial infarction, reduce complications and reduce mortality has an extremely important role. First, the commonly used thrombolytic agents and their clinical applications (a) the first generation of thrombolytic agents: urokinase and streptokinase for the first generation of thrombolytic agents, is a non-specific thrombolytic agent. The mechanism of its thrombolysis is due to urine, streptokinase can simultaneously activate plasma and thrombus plasminogen, so that it changes into active plasmin, resulting in a variety of plasma protein degradation, plasma fibrin and fibrinogen Degradation products